With new president, ABPI looks to reset focus on pricing battle

25 May 2023
abpi_logo_2022_large

The leading trade body for the UK pharmaceutical industry has appointed a new president, current Pfizer UK managing director Susan Rienow.

The Association of the British Pharmaceutical Industry (ABPI) has faced a degree of criticism in recent months over a marketing code breach from one of its members, Novo Nordisk (NOV: N).

The Danish company was  suspended from the ABPI after a “disguised” promotional campaign for weight loss treatment Saxenda (liraglutide) was uncovered. The affair led to the resignation of ABPI president Pinder Sahota, who is also UK country manager for Novo Nordisk, a diabetes care specialist.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical